分享好友 资讯首页 频道列表

China’s Center for Drug Evaluation Accepts Merck’s Application for Marketing Authorization of Pimicotinib for Treatment of Tenosynovial Giant Cell Tumor

2025-06-12 09:1518570

First global filing for potentially best-in-class TGCT treatment based on strong positive data from Phase 3 MANEUVER study
Potential for pimicotinib to be first systemic TGCT therapy approved in China, following recent granting of Priority Review by CDE
Additional applications planned in the US and other markets around the world
Not intended for Canada-, UK- or US-based media

DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading science and technology company, today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) officially accepted the company’s application for marketing authorization of pimicotinib as a Class 1 innovative drug for adult patients with tenosynovial giant cell tumors (TGCT) requiring systemic treatment. The submission follows the granting of Priority Review to pimicotinib by the CDE in May for the treatment of patients with TGCT who require systemic therapy, which is expected to expedite the review process. Pimicotinib, a potentially best-in-class investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., also has been granted breakthrough therapy designation (BTD) by the NMPA.

“With the acceptance of our application for pimicotinib and the initiation of the priority review, we aim to offer patients in China the first approved systemic therapy for TGCT, addressing a tremendous unmet need in this country,” said Hong Chow, Head of China and International, Healthcare business of Merck. “Pimicotinib has demonstrated the ability to not only shrink tumors that affect their joints but also improve outcomes like mobility, pain and stiffness, highlighting its potential to be a best-in-class treatment for TGCT. In parallel, we are working to file a New Drug Application to the US Food and Drug Administration, with additional filings planned in other markets.”

TGCT is a locally aggressive and often recurring tumor of the joints that can cause high morbidity associated with swelling, pain, stiffness, and limited mobility of the affected joints, significantly impacting daily activities and quality of life in the primarily working-age population that it affects. If left untreated or in recurrent cases, TGCT can result in irreversible damage to the bone, joint and surrounding tissues. This highlights the need for well-tolerated and effective systemic treatments that can impact tumor growth while relieving the symptoms of the disease.

The application is based on results from Part 1 of the global Phase 3 MANEUVER study, in which once-daily pimicotinib demonstrated a statistically significant improvement in the primary endpoint of objective response rate (ORR) assessed by blinded independent review committee (BIRC) compared with placebo at week 25 (54.0% vs. 3.2% for placebo; p<0.0001). The study also demonstrated statistically significant and clinically meaningful improvements in all secondary endpoints related to key patient-reported outcomes in TGCT, including improvements in active range of motion and physical function and reductions in stiffness and pain. The data were presented earlier this month at the 2025 ASCO Annual Meeting.

About MANEUVER

The pivotal Phase 3 MANEUVER study is a three-part, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of pimicotinib in patients with TGCT who require systemic therapy and have not received prior anti-CSF-1/CSF-1R therapy. The study is being conducted by Abbisko Therapeutics in China (n=45), Europe (n=28), and the US and Canada (n=21).

In the double-blind Part 1, 94 patients were randomized 2:1 to receive either 50 mg QD of pimicotinib (n=63) or placebo (n=31) for 24 weeks. The primary endpoint is objective response rate (ORR) at week 25, as measured by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by blinded independent central review in the intent-to-treat (ITT) population. Secondary endpoints include tumor volume score, active range of motion, stiffness by Numeric Rating Scale (NRS), pain by Brief Pain Inventory (BPI), and physical function measured by Patient-Reported Outcomes Measurement Information System (PROMIS).

After the double-blind Part 1, eligible patients could continue to the open-label Part 2 for up to 24 weeks of dosing, results of which are expected in mid-2025. Patients who complete Part 2 may then enter the open-label extension phase (Part 3) for extended treatment and safety follow-up.

About Pimicotinib (ABSK021)

Pimicotinib (ABSK021), which is being developed by Abbisko Therapeutics, is a novel, orally administered, highly selective and potent small-molecule inhibitor of CSF-1R. Pimicotinib was recently granted Priority Review by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) for the treatment of patients with tenosynovial giant cell tumor (TGCT) who require systemic therapy. Pimicotinib has been granted breakthrough therapy designation (BTD) by China National Medical Products Administration (NMPA) and the US Food and Drug Administration (FDA), and priority medicine (PRIME) designation from the European Medicines Agency (EMA). Merck holds worldwide commercialization rights for pimicotinib.

Advancing the Future of Cancer Care

At Merck, we strive every day to improve the futures of people living with cancer. Building on our 350-year global heritage as pharma pioneers, we are focusing our most promising science to target cancer’s deepest vulnerabilities, pursuing differentiated molecules to strike cancer at its core. By developing new therapies that can help advance cancer care, we are determined to create a world where more cancer patients will become cancer survivors. Learn more at www.merckgroup.com.

About Merck

Merck, a leading science and technology company, operates across life science, healthcare and electronics. More than 62,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2024, Merck generated sales of € 21.2 billion in 65 countries.

Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as MilliporeSigma in life science, EMD Serono in healthcare, and EMD Electronics in electronics.

All Merck press releases are distributed by e-mail at the same time they become available on the Merck website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.

 

Contacts

Media Relations
noelle.piscitelli@emdserono.com
Phone: +1 (781) 427-4351

Investor Relations
investor.relations@merckgroup.com
Phone: +49 6151 72-3321

 
反对 0
举报 0
收藏 0
打赏 0
评论 0
KIOXIA AiSAQ软件推出新版本向量搜索库,推动AI检索增强生成技术发展
全新开源软件支持根据用户需求与环境灵活平衡容量和性能 东京--(美国商业资讯)--为持续优化固态硬盘(SSD)的使用,提升检索增强生成(RAG)系统中AI向量数据库搜索的可用性,全球存储解决方案领导者Kioxia Corporation今日宣布更新其KIOXIA AiSAQ™(全存储型乘积量化近似最近邻搜索)软件。此次新开源版本引入了灵活控制功能,使系统架构师能够在搜索性能与向量数量之间定义平衡点——这两个因素在系统SSD存储的固定容量中相互制约。这一成果带...

0评论2025-07-071118

诺为泰荣获Frost & Sullivan“2025年全球生物技术CRO公司奖”
澳大利亚悉尼--(美国商业资讯)--凭借卓越的创新能力、客户服务以及国际影响力,Novotech(诺为泰)荣获弗若斯特沙利文 (Frost & Sullivan,简称“沙利文”) 颁发的“2025年全球生物技术CRO公司奖”( 2025 Global Biotechnology Contract Research Organization (CRO) Company of the Year)。 本新闻稿包含多媒体。此处查看新闻稿全文...

0评论2025-07-071259

Pickering Interfaces推出全新高速PXI旋转变压器仿真模块
精准赋能航空航天与汽车行业伺服系统测试全新PXI与PXIe仿真模块支持高达130,000转/分钟的旋转速度,满足新一代伺服系统测试需求 英国克拉克顿海滨--(美国商业资讯)--模块化信号切换与仿真解决方案全球领先供应商 Pickering Interfaces 今日宣布,旗下广受欢迎的PXI(41-670)与PXIe(43-670)系列LVDT、RVDT及旋转变压器仿真模块现已全面升级,支持高达130,000转/分钟的高速旋转变压器仿真,旨在满足航空航天、汽车及国防等关键行业对高性能伺服系统测...

0评论2025-07-071059

ISDA和Ant International牵头撰写关于“守护者计划”下代币化银行负债用于外汇结算和跨境支付的新行业报告
该报告基于共享账本技术以及共同牵头方和“守护者计划”外汇工作组成员的行业专业知识编写而成 报告包含了关于利用代币化银行负债和共享账本的建议原则,以推动行业对代币化的采用,实现全天候实时外汇结算,并为全球企业降低成本 新加坡--(美国商业资讯)--国际互换与衍生品协会(ISDA)和Ant International牵头“守护者计划”(Project Guardian)外汇行业小组,撰写了一份关于在跨境支付和外汇结算中实施代币化银行负债和共享账本的新报告。 本新闻...

0评论2025-07-071050

Venture Global宣布与PETRONAS签署20年购销协议
弗吉尼亚州阿灵顿--(美国商业资讯)-- Venture Global, Inc. (NYSE: VG)今日宣布,与马来西亚国有石油天然气公司PETRONAS的子公司PETRONAS LNG Ltd. (PLL)签署一份新的20年期购销协议(SPA)。根据协议条款,PETRONAS将在20年内每年从Venture Global的第三个设施CP2 LNG每年采购100万吨液化天然气(LNG)。这是对Venture Global与PETRONAS关于每年从Plaquemines LNG设施采购1...

0评论2025-07-071418

穩定幣需求激增,AMINA 銀行宣佈成為全球首家支援 Ripple USD (RLUSD) 的金融機構
受瑞士法規監管的 AMINA 銀行將擴大穩定幣服務,率先提供 RLUSD 的託管與交易 瑞士楚格--(美國商業資訊)-- AMINA Bank AG(以下簡稱「AMINA 銀行」)是一間受瑞士金融市場監管局 (FINMA) 監管,業務遍及全球的加密貨幣銀行。銀行今日宣佈,成為全球首家直接支援 Ripple USD (RLUSD) 的銀行。RLUSD 是一款與美元 1:1 掛鉤的穩定幣,結合了穩定性、高效率與合規優勢。服務上線初期,AMINA 的客戶即可使用 RLUSD 的託管與交易服務,為未來...

0评论2025-07-071348

2025-2026年世界品牌大奖(动物类)表彰全球顶尖宠物与动物品牌
伦敦--(美国商业资讯)-- 2025-2026年世界品牌大奖(World Branding Awards)动物类别奖(Animalis Edition)迎来第五届盛会,汇聚全球顶尖宠物与动物品牌。这些品牌因其杰出成就而备受赞誉,被评为国家、地区和全球优胜品牌。 颁奖盛典在维也纳著名的霍夫堡宫隆重举行,来自宠物食品、零售、健康护理、宠物展会及水族用品等多元领域的获奖品牌齐聚一堂。当晚活动由Mounia Berrada-Gouzi女士优雅主持,最终以一场致敬品牌卓越成就的恢弘庆典圆满落幕。...

0评论2025-07-071174

芯原推出经市场验证的ZSP5000视觉核心系列,扩展其面向边缘智能的数字信号处理器IP组合
具备可扩展的架构和指令集,赋能计算机视觉和图像应用 中国上海--(美国商业资讯)--芯原股份(芯原,股票代码:688521.SH)今日正式发布ZSP5000系列IP。该产品线基于公司第五代经硅验证的数字信号处理器(DSP)架构,采用高可扩展性和低功耗的设计,并针对计算机视觉、嵌入式人工智能等计算密集型应用进行了深度优化,结合架构的可配置能力,该系列IP可为各类边缘设备提供兼具能效优势和计算效率的优秀解决方案。 ZSP5000系列包含ZSP5000、ZSP5000UL、ZSP5000L及ZS...

0评论2025-07-071161

LambdaTest宣布与Appium深化战略合作
此举将通过LambdaTest庞大的真实设备云加速规模化移动测试自动化,实现无与伦比的准确性、速度与全球覆盖。 旧金山--(美国商业资讯)--统一的智能AI与云工程平台LambdaTest近日宣布,其已成为全球应用最广泛的移动自动化开源框架Appium的战略赞助商。此次合作旨在通过将Appium的功能集成到LambdaTest基于云的分布式测试平台中,来大幅简化并加速移动测试自动化流程。 LambdaTest拥有活跃的开源计划,为社区项目提供访问LambdaTest测试基础设施的权限,使维...

0评论2025-07-041152

SE Labs 奖项力证 NetApp 全球最安全存储的卓越地位
NetApp 荣膺 2025 年度 SE Labs 企业数据保护奖 美国加州圣何塞--(美国商业资讯)--智能数据基础设施公司 NetApp® (NASDAQ: NTAP) 今日宣布,公司凭借在网络安全领域的卓越表现,在 SE LABS® 2025 年度评选中备受赞誉。NetApp 荣获 2025 年度 SE Labs 企业数据保护奖,再次印证了其作为全球最安全存储提供商的领先地位。 此次获奖得益于 NetApp 在网络韧性领域的卓越创新。公司推出的集成了人工智能技术的 N...

0评论2025-07-041757